Prognose des Opioidmarkts in Europa bis 2030 – Regionale Analyse – nach Produkt (sofort freisetzendes, kurz wirkendes Opioid und retardiertes, lang wirkendes Opioid), Anwendung (Schmerzbehandlung, Anästhesie, Durchfall- und Hustenstillung, Entwöhnung und andere), Verabreichungsweg (oral, injizierbar und transdermales Pflaster) und Vertriebskanal (Krankenhausapotheken und Einzelhandelsapotheken)
Steigende Fälle chronischer Schmerzen treiben den europäischen Opioidmarkt an
Chronische Krankheiten wie Herz-Kreislauf-Erkrankungen, Krebs, Erkrankungen des Bewegungsapparats und neurovaskuläre Erkrankungen beeinträchtigen die Gesundheit eines Menschen kritisch, indem sie die Immunität schwächen. Darüber hinaus leiden viele Patienten, die an diesen Krankheiten leiden, unter chronischen Schmerzen. Die oben genannten Krankheiten treten am häufigsten bei Erwachsenen und der geriatrischen Bevölkerung auf. Dennoch nehmen die Fälle dieser Krankheiten auch bei Kindern deutlich zu. Chronische Schmerzen treten auch häufig bei Sportlern, Athleten und Personen auf, die mit früheren Verletzungen leben. Laut einer im NCBI (National Center for Biotechnology Information) veröffentlichten Studie leiden weltweit 20 % aller Erwachsenen unter Schmerzen, und bei 10 % werden jährlich chronische Schmerzen neu diagnostiziert. Obwohl Schmerzen alle Bevölkerungsgruppen unabhängig von Geschlecht, Rasse/Ethnie, Einkommen, Alter oder Wohnort betreffen, sind sie weltweit nicht gleichmäßig verteilt. Verschreibungspflichtige Opioide wie Hydrocodon, Oxycodon und Morphin sind wirksame schmerzstillende Medikamente, die zur Behandlung von Schmerzen eingesetzt werden, die durch Verletzungen, Operationen und Erkrankungen wie Krebs und Arthritis verursacht werden. Die zunehmende Verschreibung von Opioiden ist auf Versicherungserstattungsprogramme zurückzuführen, die Opioide gegenüber alternativen Schmerzbehandlungen begünstigen, auf Kostenstrukturen, die eine effizientere Versorgung fördern, und auf Beurteilungen, die Patientenzufriedenheit mit wirksamer Schmerzbehandlung kombinieren. Aufgrund der Vorteile von Opioiden in der Schmerzbehandlung steigt die Nachfrage unter Patienten mit chronischen Erkrankungen.
Überblick über den Opioidmarkt in Europa
Der europäische Opioidmarkt ist in Deutschland, Großbritannien, Frankreich, Italien, Spanien und den Rest Europas unterteilt. Europa nimmt auf dem europäischen Opioidmarkt eine bedeutende Position ein und wird im Prognosezeitraum voraussichtlich ein starkes Marktwachstum erleben. Das Marktwachstum in der Region ist hauptsächlich auf die steigende Verbreitung von Krankheiten zurückzuführen, die chronische Schmerzen verursachen (wie Arthritis, Schmerzen im unteren Rückenbereich und Fibromyalgie) und die steigende Verfügbarkeit von Medikamenten zur Behandlung der Abhängigkeit von Opioiddrogen (wie Heroin). Beispielsweise ist Methadon der am häufigsten verschriebene Opioidagonist in Europa und wird bei 75 % der Patienten zur Erhaltungstherapie mit Opioidagonisten verwendet. Buprenorphin ist der am zweithäufigsten verwendete Opioidagonist in der Region. Es ist jedoch eine der am häufigsten verwendeten Opioid-Erhaltungstherapien in Kroatien, Zypern, der Tschechischen Republik, Finnland, Frankreich und Schweden. Codein ist der primäre Agonist, der in Zypern und Deutschland verwendet wird, während Diacetylmorphin derjenige ist, der üblicherweise in Belgien, Dänemark, Deutschland, den Niederlanden, Spanien, Großbritannien und Irland verwendet wird.
Umsatz und Prognose des europäischen Opioidmarkts bis 2030 (Mio. USD)
Segmentierung des europäischen Opioidmarkts
Der europäische Opioidmarkt ist nach Produkt, Anwendung, Verabreichungsweg, Vertriebskanal und Land kategorisiert.
Basierend auf dem Produkt ist der europäische Opioidmarkt segmentiert in Opioide mit sofortiger Wirkstofffreisetzung und Opioide mit verlängerter Wirkstofffreisetzung und langer Wirkstofffreisetzung. Das Segment der Opioide mit sofortiger Wirkstofffreisetzung und kurzer Wirkstofffreisetzung hatte 2022 einen größeren Marktanteil. Das Opioid mit sofortiger Wirkstofffreisetzung und kurzer Wirkstofffreisetzung ist weiter unterteilt in Oxycodon, Hydrocodon, Tramadol, Codin, Propoxyphen und andere. Das Opioid mit verlängerter Wirkstofffreisetzung und langer Wirkungsdauer ist weiter unterteilt in Oxycodon, Fentanyl, Morphin, Methadon und andere.
In Bezug auf die Anwendung ist der europäische Opioidmarkt in Schmerzbehandlung, Anästhesie, Durchfallunterdrückung, Hustenunterdrückung, Entwöhnung und andere unterteilt. Das Segment Schmerzbehandlung hatte 2022 den größten Marktanteil.
Nach Verabreichungsweg ist der europäische Opioidmarkt in orale, injizierbare und transdermale Pflaster unterteilt. Das orale Segment hatte 2022 den größten Marktanteil.
Nach Vertriebskanal ist der europäische Opioidmarkt in Krankenhausapotheken und Einzelhandelsapotheken unterteilt. Das Segment Krankenhausapotheken hatte 2022 einen größeren Marktanteil.
Nach Ländern ist der europäische Opioidmarkt in Großbritannien, Deutschland, Frankreich, Italien, Spanien und den Rest von Europa unterteilt. Das Vereinigte Königreich dominierte 2022 den europäischen Opioidmarkt.
Endo International plc, Mallinckrodt Plc, Neuraxpharm Pharmaceuticals SL, Hikma Pharmaceuticals Plc, Rusan Pharma Ltd und Teva Pharmaceutical Industries Ltd sind einige der führenden Unternehmen auf dem europäischen Opioidmarkt.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Opioids Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Surging Chronic Pain Incidence
4.1.2 Increasing Geriatric Population
4.2 Market Restraints
4.2.1 Increasing Drug Abuse
4.3 Market Opportunities
4.3.1 Strategic Initiatives by Market Players
4.4 Impact of Drivers and Restraints:
5. Opioids Market - Europe Analysis
5.1 Europe Opioids Market Overview
5.2 Europe Opioids Market Revenue (US$ Million), 2020-2030
5.3 Europe Opioids Market Forecast Analysis
6. Europe Opioids Market Analysis - by Product
6.1 Immediate Release Short Acting Opioid
6.1.1 Overview
6.1.2 Immediate Release Short Acting Opioid: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
6.1.2.1 Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
6.2 Extended Release Long-Acting Opioid
6.2.1 Overview
6.2.2 Extended Release Long-Acting Opioid: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
6.2.2.1 Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
7. Europe Opioids Market Analysis - by Application
7.1 Pain Management
7.1.1 Overview
7.1.2 Pain Management: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Anesthesia
7.2.1 Overview
7.2.2 Anesthesia: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Diarrhea Suppression
7.3.1 Overview
7.3.2 Diarrhea Suppression: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Cough Suppression
7.4.1 Overview
7.4.2 Cough Suppression: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.5 De-Addiction
7.5.1 Overview
7.5.2 De-Addiction: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Opioids Market Analysis - by Route of Administration
8.1 Oral
8.1.1 Overview
8.1.2 Oral: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.2 Injectable
8.2.1 Overview
8.2.2 Injectable: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Transdermal Patch
8.3.1 Overview
8.3.2 Transdermal Patch: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Opioids Market Analysis - by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Overview
9.1.2 Hospital Pharmacies: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
9.2 Retail Pharmacies
9.2.1 Overview
9.2.2 Retail Pharmacies: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Opioids Market - Country Analysis
10.1 Europe
10.1.1 Europe: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
10.1.1.1 Europe: Opioids Market - Revenue and Forecast Analysis - by Country
10.1.1.2 United Kingdom: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 United Kingdom: Europe Opioids Market Breakdown, by Product
10.1.1.2.2 United Kingdom: Europe Opioids Market Breakdown, by Immediate Release Short Acting Opioid
10.1.1.2.3 United Kingdom: Europe Opioids Market Breakdown, by Extended Release Long-Acting Opioid
10.1.1.2.4 United Kingdom: Europe Opioids Market Breakdown, by Application
10.1.1.2.5 United Kingdom: Europe Opioids Market Breakdown, by Route of Administration
10.1.1.2.6 United Kingdom: Europe Opioids Market Breakdown, by Distribution Channel
10.1.1.3 Germany: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Germany: Europe Opioids Market Breakdown, by Product
10.1.1.3.2 Germany: Europe Opioids Market Breakdown, by Immediate Release Short Acting Opioid
10.1.1.3.3 Germany: Europe Opioids Market Breakdown, by Extended Release Long-Acting Opioid
10.1.1.3.4 Germany: Europe Opioids Market Breakdown, by Application
10.1.1.3.5 Germany: Europe Opioids Market Breakdown, by Route of Administration
10.1.1.3.6 Germany: Europe Opioids Market Breakdown, by Distribution Channel
10.1.1.4 France: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 France: Europe Opioids Market Breakdown, by Product
10.1.1.4.2 France: Europe Opioids Market Breakdown, by Immediate Release Short Acting Opioid
10.1.1.4.3 France: Europe Opioids Market Breakdown, by Extended Release Long-Acting Opioid
10.1.1.4.4 France: Europe Opioids Market Breakdown, by Application
10.1.1.4.5 France: Europe Opioids Market Breakdown, by Route of Administration
10.1.1.4.6 France: Europe Opioids Market Breakdown, by Distribution Channel
10.1.1.5 Italy: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Italy: Europe Opioids Market Breakdown, by Product
10.1.1.5.2 Italy: Europe Opioids Market Breakdown, by Immediate Release Short Acting Opioid
10.1.1.5.3 Italy: Europe Opioids Market Breakdown, by Extended Release Long-Acting Opioid
10.1.1.5.4 Italy: Europe Opioids Market Breakdown, by Application
10.1.1.5.5 Italy: Europe Opioids Market Breakdown, by Route of Administration
10.1.1.5.6 Italy: Europe Opioids Market Breakdown, by Distribution Channel
10.1.1.6 Spain: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Spain: Europe Opioids Market Breakdown, by Product
10.1.1.6.2 Spain: Europe Opioids Market Breakdown, by Immediate Release Short Acting Opioid
10.1.1.6.3 Spain: Europe Opioids Market Breakdown, by Extended Release Long-Acting Opioid
10.1.1.6.4 Spain: Europe Opioids Market Breakdown, by Application
10.1.1.6.5 Spain: Europe Opioids Market Breakdown, by Route of Administration
10.1.1.6.6 Spain: Europe Opioids Market Breakdown, by Distribution Channel
10.1.1.7 Rest of Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 Rest of Europe: Opioids Market Breakdown, by Product
10.1.1.7.2 Rest of Europe: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
10.1.1.7.3 Rest of Europe: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
10.1.1.7.4 Rest of Europe: Opioids Market Breakdown, by Application
10.1.1.7.5 Rest of Europe: Opioids Market Breakdown, by Route of Administration
10.1.1.7.6 Rest of Europe: Opioids Market Breakdown, by Distribution Channel
11. Industry Landscape
11.1 Overview
11.2 Growth Strategies in Opioids Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Endo International plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Mallinckrodt Plc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Neuraxpharm Pharmaceuticals SL
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Hikma Pharmaceuticals Plc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Rusan Pharma Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Teva Pharmaceutical Industries Ltd
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
List of Tables
Table 1. Europe Opioids Market Segmentation
Table 2. Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 4. Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 5. Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 6. Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 7. Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 8. Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 9. Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Country
Table 10. United Kingdom: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 11. United Kingdom: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 12. United Kingdom: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 13. United Kingdom: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 14. United Kingdom: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 15. United Kingdom: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 16. Germany: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 17. Germany: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 18. Germany: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 19. Germany: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 20. Germany: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 21. Germany: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 22. France: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 23. France: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 24. France: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 25. France: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 26. France: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 27. France: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 28. Italy: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 29. Italy: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 30. Italy: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 31. Italy: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 32. Italy: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 33. Italy: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 34. Spain: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 35. Spain: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 36. Spain: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 37. Spain: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 38. Spain: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 39. Spain: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 40. Rest of Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product
Table 41. Rest of Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
Table 42. Rest of Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid
Table 43. Rest of Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 44. Rest of Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 45. Rest of Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 46. Recent Organic Growth Strategies in Opioids Market
Table 47. Recent Inorganic Growth Strategies in the Opioids Market
Table 48. Glossary of Terms, Opioids Market
List of Figures
Figure 1. Europe Opioids Market Segmentation, by Country
Figure 2. Europe Opioids Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Opioids Market Revenue (US$ Million), 2020-2030
Figure 5. Europe Opioids Market Share (%) - by Product (2022 and 2030)
Figure 6. Immediate Release Short Acting Opioid: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Extended Release Long-Acting Opioid: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Europe Opioids Market Share (%) - by Application (2022 and 2030)
Figure 9. Pain Management: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Anesthesia: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Diarrhea Suppression: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Cough Suppression: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. De-Addiction: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Europe Opioids Market Share (%) - by Route of Administration (2022 and 2030)
Figure 16. Oral: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Injectable: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Transdermal Patch: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Europe Opioids Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 20. Hospital Pharmacies: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Retail Pharmacies: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Europe: Opioids Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 23. Europe: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 24. United Kingdom: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Germany: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. France: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. Italy: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Spain: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Rest of Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Growth Strategies in Opioids Market
- Endo International plc
- Mallinckrodt Plc
- Neuraxpharm Pharmaceuticals SL
- Hikma Pharmaceuticals Plc
- Rusan Pharma Ltd
- Teva Pharmaceutical Industries Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe opioids market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe opioids market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe opioids market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.